IMR Press / FBS / Volume 3 / Issue 1 / DOI: 10.2741/S139

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Vulvar cancer as a target for molecular medicine
Show Less
1 Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 5a Pawinskiego Street, 02-106, Warsaw, Poland
2 Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine, ul. Szaserow 128, 04-141 Warsaw, Poland
3 Department of Otolaryngology, Czerniakowski Hospital, Medical University of Warsaw, 19/25 Stępinska Street, 00-739 Warsaw, Poland
4 IIND Department of Gynecology, Lublin Medical University, Lublin, Poland

*Author to whom correspondence should be addressed.

Academic Editor: Anna Czarnecka

Front. Biosci. (Schol Ed) 2011, 3(1), 136–144;
Published: 1 January 2011
(This article belongs to the Special Issue Frontiers in molecular medicine)

Vulvar carcinoma is a rare female genital neoplasm. Although numerous molecular defects in vulvar carcinomas have been reported until now, no molecular markers that could be applied in daily clinical work have been identified so far. However, there is emerging evidence that specific mutations and gene expression patterns may be used as diagnostic tools in oncology. In this article we systematically review genetic alterations that may contribute to the development and progression of vulvar carcinoma. We conclude by suggesting molecular markers of potential clinical value in the diagnostics of this type of cancer.

Back to top